We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-12.12%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.23B
AUM Growth
-$138M
Cap. Flow
+$87.1M
Cap. Flow %
7.07%
Top 10 Hldgs %
28.99%
Holding
134
New
17
Increased
54
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
STJ
St Jude Medical
STJ
+$37.8M
2
AET
Aetna Inc
AET
+$26.5M
3
ACHC icon
Acadia Healthcare
ACHC
+$23.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$21.1M
5
CHMA
Chiasma, Inc. Common Stock
CHMA
+$13M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$42.2M
2
HUM icon
Humana
HUM
+$25.2M
3
THOR
THORATEC CORPORATION
THOR
+$24.5M
4
BHC icon
Bausch Health
BHC
+$17.9M
5
MCK icon
McKesson
MCK
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 76.04%
2 Financials 3.43%
3 Technology 0.48%
4 Industrials 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
26
Travere Therapeutics
TVTX
$5.78B
$13.9M 1.12%
683,900
+8,900
+1% +$264K
TRNX
27
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$13.5M 1.09%
660,000
– –
MCK icon
28
McKesson
MCK
$101B
$13M 1.05%
70,000
-79,500
-53% -$16.8M
EHC icon
29
Encompass Health
EHC
$12.4B
$12.9M 1.05%
424,238
+100,560
+31% +$3.5M
INCY icon
30
Incyte
INCY
$24.4B
$12.5M 1.01%
113,000
– –
ELV icon
31
Elevance Health
ELV
$85.5B
$12.3M 0.99%
87,500
+36,000
+70% +$5.41M
TMO icon
32
Thermo Fisher Scientific
TMO
$220B
$12.2M 0.99%
100,000
– –
ARDX icon
33
Ardelyx
ARDX
$997M
$11.8M 0.96%
681,500
+71,500
+12% +$1.33M
CVS icon
34
CVS Health
CVS
$122B
$11.6M 0.94%
120,000
-44,000
-27% -$4.63M
AMGN icon
35
Amgen
AMGN
$222B
$11.5M 0.93%
83,250
-72,750
-47% -$11.5M
BIIB icon
36
Biogen
BIIB
$30.7B
$11.3M 0.92%
38,650
– –
PRTA icon
37
Prothena Corp
PRTA
$450M
$11.2M 0.91%
248,000
-2,000
-0.8% -$116K
SRGA
38
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$10.6M 0.86%
62,000
– –
CHMA
39
DELISTED
Chiasma, Inc. Common Stock
CHMA
$10.4M 0.84%
+522,500
New +$13M
RARE icon
40
Ultragenyx Pharmaceutical
RARE
$2.55B
$10.3M 0.84%
107,000
+15,000
+16% +$1.72M
ZSPH
41
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$10.2M 0.83%
155,000
-4,000
-3% -$240K
ANAC
42
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$10.1M 0.82%
+86,000
New +$11.2M
CORV
43
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$10M 0.82%
1,190,000
+565,000
+90% +$5.2M
PRAH
44
DELISTED
PRA Health Sciences, Inc.
PRAH
$9.82M 0.8%
253,000
-32,000
-11% -$1.28M
MD icon
45
Pediatrix Medical
MD
$2.2B
$9.6M 0.78%
+125,000
New +$10.1M
COO icon
46
Cooper Companies
COO
$14.5B
$9.21M 0.75%
247,600
+31,600
+15% +$1.31M
TSRO
47
DELISTED
TESARO, Inc.
TSRO
$9.06M 0.74%
226,000
+9,000
+4% +$492K
ADAP
48
DELISTED
Adaptimmune Therapeutics
ADAP
$9.05M 0.73%
756,100
-148,900
-16% -$2.1M
DVA icon
49
DaVita
DVA
$11.7B
$8.83M 0.72%
122,050
– –
INSY
50
DELISTED
Insys Therapeutics, Inc.
INSY
$8.77M 0.71%
308,000
+161,000
+110% +$5.93M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Rock Springs Capital Management held 134 positions worth $1.23B, down 10% from $1.37B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $87.1M of net new capital in Q3 2015, opening 17 new positions and adding to 54 existing holdings. Its largest new stake was St Jude Medical: 530,000 shares worth $33.4M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 77% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was THORATEC CORPORATION, an estimated $24.5M trimmed.

  • Rock Springs Capital Management's largest Q3 2015 buy was St Jude Medical: 530,000 shares worth $33.4M.
  • Rock Springs Capital Management added most to Aetna Inc in Q3 2015, an estimated $26.5M increase.
  • Rock Springs Capital Management's biggest Q3 2015 reduction was THORATEC CORPORATION, cutting an estimated $24.5M.
  • Rock Springs Capital Management fully exited Medtronic in Q3 2015, selling an estimated $42.2M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.23B portfolio in Q3 2015.
  • Rock Springs Capital Management opened 17 new positions and closed 13 in Q3 2015.
  • Rock Springs Capital Management's portfolio value fell 10% quarter-over-quarter to $1.23B.

Based on Rock Springs Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.